Cameron Shand

Cameron Shand

Auto-generated profile, based on publicly available information

Cameron Shand

The Francis Crick Institute, Software Engineering & AI STP, London, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2021 in SoftwareX
Verified
Journal Article
Open access
LALeon M. Aksman
Leon M. Aksman
PWPeter Wijeratne
Peter Wijeratne
NONeil Oxtoby
Neil Oxtoby
AEArman Eshaghi
Arman Eshaghi
CSCameron Shand
Cameron Shand
AYAlexandra L. Young
Alexandra L. Young
Progressive disorders are highly heterogeneous. Symptom-based clinical classification of these disorders may not reflect the underlying pathobiology. Data-driven subtyping and staging of patients has the potential to disentangle the complex spatiotemporal patterns of disease progression. Tools that enable this are in high demand from clinical and treatment-development communities. Here we describe the pySuStaIn software package, a Python-based implementation of the Subtype and Stage Inference (SuStaIn) algorithm. SuStaIn unravels the complexity of heterogeneous diseases by inferring multiple disease progression patterns (subtypes) and individual severity (stages) from cross-sectional data. The primary aims of pySuStaIn are to enable widespread application and translation of SuStaIn via an accessible Python package that supports simple extension and generalization to novel modelling situations within a single, consistent architecture.

10 September 2025 in Nature Methods
Verified
Journal Article
Open access
PDF file
DKDaniel Krentzel
Daniel Krentzel
MEMatouš Elphick
Matouš Elphick
MDMarie-Charlotte Domart
Marie-Charlotte Domart
CPChristopher J. Peddie
Christopher J. Peddie
RLRomain F. Laine
Romain F. Laine
MJMartin L. Jones
Martin L. Jones
Volume correlative light and electron microscopy (vCLEM) is a powerful imaging technique that enables the visualization of fluorescently labeled proteins within their ultrastructural context. Currently, vCLEM alignment relies on time-consuming and subjective manual methods. This paper presents CLEM-Reg, an algorithm that automates the three-dimensional alignment of vCLEM datasets by leveraging probabilistic point cloud registration techniques. Point clouds are derived from segmentations of common structures in each modality, created by state-of-the-art open-source methods. CLEM-Reg drastically reduces the registration time of vCLEM datasets to a few minutes and achieves correlation of fluorescent signal to submicron target structures in electron microscopy on three newly acquired vCLEM benchmark datasets. CLEM-Reg was then used to automatically obtain vCLEM overlays to unambiguously identify TGN46-positive transport carriers involved in protein trafficking between the trans-Golgi network and plasma membrane. Datasets are available on EMPIAR and BioStudies, and a napari plugin is provided to aid end-user adoption.

13 July 2019
Verified
Conference Paper
Open access
CSCameron Shand
Cameron Shand
RARichard Allmendinger
Richard Allmendinger
JHJulia Handl
Julia Handl
AWAndrew Webb
Andrew Webb
JKJohn Keane
John Keane
Synthetic datasets play an important role in evaluating clustering algorithms, as they can help shed light on consistent biases, strengths, and weaknesses of particular techniques, thereby supporting sound conclusions. Despite this, there is a surprisingly small set of established clustering benchmark data, and many of these are currently handcrafted. Even then, their difficulty is typically not quantified or considered, limiting the ability to interpret algorithmic performance on these datasets. Here, we introduce HAWKS, a new data generator that uses an evolutionary algorithm to evolve cluster structure of a synthetic data set. We demonstrate how such an approach can be used to produce datasets of a pre-specified difficulty, to trade off different aspects of problem difficulty, and how these interventions directly translate into changes in the clustering performance of established algorithms.

21 December 2021 in IEEE Transactions on Evolutionary Computation
Verified
Journal Article
Closed access
CSCameron Shand
Cameron Shand
RARichard Allmendinger
Richard Allmendinger
JHJulia Handl
Julia Handl
AWAndrew Webb
Andrew Webb
JKJohn Keane
John Keane
Comprehensive benchmarking of clustering algorithms is rendered difficult by two key factors: (i) the elusiveness of a unique mathematical definition of this unsupervised learning approach and (ii) dependencies between the generating models or clustering criteria adopted by some clustering algorithms and indices for internal cluster validation. Consequently, there is no consensus regarding the best practice for rigorous benchmarking, and whether this is possible at all outside the context of a given application. Here, we argue that synthetic datasets must continue to play an important role in the evaluation of clustering algorithms, but that this necessitates constructing benchmarks that appropriately cover the diverse set of properties that impact clustering algorithm performance. Through our framework, HAWKS, we demonstrate the important role evolutionary algorithms play to support flexible generation of such benchmarks, allowing simple modification and extension. We illustrate two possible uses of our framework: (i) the evolution of benchmark data consistent with a set of hand-derived properties and (ii) the generation of datasets that tease out performance differences between a given pair of algorithms. Our work has implications for the design of clustering benchmarks that sufficiently challenge a broad range of algorithms, and for furthering insight into the strengths and weaknesses of specific approaches.

10 February 2023 in medRxiv
Verified
Preprint
Open access
PDF file
CSCameron Shand
Cameron Shand
PMPawel J. Markiewicz
Pawel J. Markiewicz
DCDavid M. Cash
David M. Cash
DADaniel C. Alexander
Daniel C. Alexander
MDMichael C. Donohue
Michael C. Donohue
TIThe Alzheimer’s Disease Neuroimaging Initiative
The Alzheimer’s Disease Neuroimaging Initiative
Importance: Undetected biological heterogeneity adversely impacts trials in Alzheimer’s disease because rate of cognitive decline — and perhaps response to treatment — differs in subgroups. Recent results show that data-driven approaches can unravel the heterogeneity of Alzheimer’s disease progression. The resulting stratification is yet to be leveraged in clinical trials. Objective: Investigate whether image-based data-driven disease progression modelling could identify baseline biological heterogeneity in a clinical trial, and whether these subgroups have prognostic or predictive value. Design: Screening data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer Disease (A4) Study collected between April 2014 and December 2017, and longitudinal data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) observational study downloaded in February 2022 were used. Setting: The A4 Study is an interventional trial involving 67 sites in the US, Canada, Australia, and Japan. ADNI is a multi-center observational study in North America. Participants: Cognitively unimpaired amyloid-positive participants with a 3-Tesla T1-weighted MRI scan. Amyloid positivity was determined using florbetapir PET imaging (in A4) and CSF Aβ(1-42) (in ADNI). Main Outcomes and Measures: Regional volumes estimated from MRI scans were used as input to the Subtype and Stage Inference (SuStaIn) algorithm. Outcomes included cognitive test scores and SUVr values from florbetapir and flortaucipir PET. Results: We included 1,240 Aβ+ participants (and 407 Aβ− controls) from the A4 Study, and 731 A4-eligible ADNI participants. SuStaIn identified three neurodegeneration subtypes — Typical, Cortical, Subcortical — comprising 523 (42%) individuals. The remainder are designated subtype zero (insufficient atrophy). Baseline PACC scores (A4 primary outcome) were significantly worse in the Cortical subtype (median = -1.27, IQR=[-3.34,0.83]) relative to both subtype zero (median=-0.013, IQR=[-1.85,1.67], P<.0001) and the Subcortical subtype (median=0.03, IQR=[-1.78,1.61], P=.0006). In ADNI, over a four-year period (comparable to A4), greater cognitive decline in the mPACC was observed in both the Typical (−0.23/yr; 95% CI, [-0.41,-0.05]; P=.01) and Cortical (−0.24/yr; [-0.42,-0.06]; P=.009) subtypes, as well as the CDR-SB ( Typical : +0.09/yr, [0.06,0.12], P<.0001; and Cortical : +0.07/yr, [0.04,0.10], P<.0001). Conclusions and Relevance: In a large secondary prevention trial, our image-based model detected neurodegenerative heterogeneity predictive of cognitive heterogeneity. We argue that such a model is a valuable tool to be considered in future trial design to control for previously undetected variance. Key Points: Question: Can MRI-based computational subtypes of preclinical neurodegeneration predict cognitive outcomes? Findings: In this cross-sectional analysis of magnetic resonance imaging (MRI) data at screening (pre-randomization) in the preclinical Anti-Amyloid Treatment in Asymptomatic Alzheimer disease (A4) Study, we detected considerable neurodegenerative heterogeneity using data-driven disease progression modelling. The MRI-based computational subtypes identified by Subtype and Stage Inference (SuStaIn) differed in baseline cognitive test scores (A4) and in longitudinal cognitive decline (ADNI), with sufficient heterogeneity to potentially obscure treatment effect in A4 trial outcomes. Meaning: Data-driven disease progression modelling of screening MRI scans can predict heterogeneity in cognitive performance/decline and potentially reduce heterogeneity in future clinical trials.

28 January 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
EPEmma Prevot
Emma Prevot
CSCameron Shand
Cameron Shand
FIFor Alzheimer’S Disease Neuroimaging Initiative
For Alzheimer’S Disease Neuroimaging Initiative
NONeil Oxtoby
Neil Oxtoby
Background: Alzheimer's disease (AD) exhibits substantial clinical and biological heterogeneity, complicating efforts in treatment and intervention development. While new computational methods offer insights into AD subtyping and disease staging, the reproducibility of these subtypes across datasets remains understudied, particularly concerning the robustness of subtype definitions when validated on diverse databases. Objective: This study evaluates the robustness of the AD progression subtypes identified by the Subtype and Stage Inference (SuStaIn) algorithm on a larger and more diverse cohort. Methods: We extracted T1-weighted MRI data for 5444 subjects from ANMerge, OASIS, and ADNI datasets, forming four independent cohorts. Each cohort was analyzed with SuStaIn under two conditions: one using the full cohort, including cognitively normal controls, and another excluding controls to test subtype robustness. Results: Results confirm the three primary atrophy subtypes identified in earlier studies: Typical, Cortical, and Subcortical, as well as the emergence of rare and atypical AD variants such as posterior cortical atrophy. Notably, each subtype displayed varying robustness to the inclusion of controls, with certain subtypes, like the Subcortical subtype, more influenced by cohort composition. Conclusions: This investigation underscores SuStaIn's reliability for defining stable AD subtypes and suggests its utility in clinical stratification for trials and diagnosis. However, our findings also highlight the need for improved dataset ethnic and demographic diversity, particularly in terms of ethnic representation, to enhance generalizability and support broader clinical application.